HCW Biologics Inc. (HCWB)
$1.48-7.50%Close
SELLCRISIS · day 27
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $514,509
- Beta
- 2.42
- P/E (TTM)
- -0.03
- Short % float
- 20.44%
- Days to cover
- 1.0
- SI change
- +557.1%
- 1W
- -9.76%
- 1M
- -33.93%
- vs SPY 1W
- -10.18%
- vs SPY 1M
- -35.99%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 2
- GROWTH
- 37
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-85.3%
REV YoY-
ROE-142.2%
EPS YoY-
ROA-18.4%
GROSS96
OP-92
NET-73
[VALUATION]
P/E TTM-0.03
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B0.07
P/FCF-
EV/EBITDA-1.49
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E88.34
ALTMAN Z-
CURR RATIO0.06
ND/EBITDA-
BETA2.42
Company news
FAQ
- What is LOPJLB’s current signal on HCWB?
- LOPJLB’s latest quantitative signal on HCW Biologics Inc. (HCWB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is HCWB in?
- HCW Biologics Inc. (HCWB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does HCW Biologics Inc. (HCWB) do?
- HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for pat…